Pharma BD Deal Intelligence
DUSA's Levulan/BLU-U franchise survived and was incrementally improved under Sun Pharma, but a $20.75M DOJ fraud settlement over Levulan marketing practices and no disclosed standalone financial upside make this a middling, reputationally scarred deal rather than a clean win.
Full analysis, sources & comparables →Sun Pharma's $230M tender offer at $8/share (38% premium) gives the Indian generics leader a US-approved branded dermatology platform in PDT — its first…
DUSA has proven technical capabilities in photodynamic skin treatments, with USFDA approved manufacturing. The acquisition gives Sun Pharma the FDA-approved…
PitchBook records the DUSA acquisition by Sun's Caraco Pharmaceutical Laboratories subsidiary at $230M, completed via tender offer in December 2012 with no…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Sun Pharma tender offer at $8/share cash for DUSA (~$230M; 38% premium). Acquired Levulan photodynamic therapy platform for AK and acne, providing Sun's first US dermatology branded entry.
DUSA's Levulan/BLU-U franchise survived and was incrementally improved under Sun Pharma, but a $20.75M DOJ fraud settlement over Levulan marketing practices and no disclosed standalone financial upside make this a middling, reputationally scarred deal rather than a clean win.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. / DUSA Pharmaceuticals, Inc. (this deal) | 2012 | $230M | 49 |
| Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited | 2014 | $4.0B | 66 |
| Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited | 2015 | $4.0B | 52 |
| Sun Pharmaceutical Industries Ltd. / URL Pharma, Inc. (generics business) | 2012 | $60M | 34 |
| Sun Pharmaceutical Industries Ltd. / Organon & Co. | 2026 | $11.8B | — |
| Sun Pharmaceutical Industries Ltd. / Checkpoint Therapeutics, Inc. | 2025 | $355M | — |
| Ciba-Geigy AG / Sandoz AG | 1996 | $36.3B | 98 |
← Browse all deals · How we score deals
More: 2012 deals · Sun Pharmaceutical Industries Ltd. deals · Dermatology deals